FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws
Decision Shows Impact Of Actavis Beyond Cases Involving Reverse-Payment Settlements
In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.
